How low should we go? The search for balance in management of small human epidermal growth factor receptor 2-positive breast cancers
- PMID: 24888811
- DOI: 10.1200/JCO.2014.55.7249
How low should we go? The search for balance in management of small human epidermal growth factor receptor 2-positive breast cancers
Comment in
-
Combination trastuzumab and chemotherapy may have a role in women with small, node-negative, human epidermal growth factor receptor 2-positive breast cancer.J Clin Oncol. 2015 Jan 1;33(1):124-5. doi: 10.1200/JCO.2014.58.2965. Epub 2014 Nov 17. J Clin Oncol. 2015. PMID: 25403210 No abstract available.
-
Reply to H.L. McArthur et al.J Clin Oncol. 2015 Jan 1;33(1):125. doi: 10.1200/JCO.2014.58.9655. Epub 2014 Nov 17. J Clin Oncol. 2015. PMID: 25403214 No abstract available.
Comment on
-
Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.J Clin Oncol. 2014 Jul 10;32(20):2151-8. doi: 10.1200/JCO.2013.52.0858. Epub 2014 Jun 2. J Clin Oncol. 2014. PMID: 24888815
-
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.J Clin Oncol. 2014 Jul 10;32(20):2142-50. doi: 10.1200/JCO.2013.53.1608. Epub 2014 Jun 2. J Clin Oncol. 2014. PMID: 24888816 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
